Lantern Pharma's LP-184 Phase 1a Trial Achieves All Primary Endpoints with Promising Safety Profile and Antitumor Activity in Advanced Solid Tumors.

Corbus Pharmaceuticals Holdings has received Fast-Track Designation from the FDA for its drug targeting head and neck cancer. The company's pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells. Additionally, the company has CRB-913, a cannabinoid type-1 receptor inverse agonist for obesity treatment.